Humacyte, Inc. — Director's Dealing 2022

Jun 13, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2022-06-09

Reporting Person: Niklason Laura E (Director, President, CEO and Director, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-09	Stock Options (right to buy)	$4.34	A	8500	Acquired	2032-06-09	Common Stock (8500.0)	Indirect

Footnotes

F1: The first 25% of the option becomes exercisable on June 9, 2023, after which 1/48 of the option will become exercisable on the 9th of each month through June 9, 2026.